← Back to Clinical Trials
Recruiting NCT07438028

NCT07438028 Energy Reduction and Umami

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07438028
Status Recruiting
Phase —
Sponsor Wageningen University
Condition Sensory Testing
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2027-02-11
Primary Completion 2027-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Regular energy density, no added umamiRegular energy density, with added umamiLowered energy density, with added umami

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2027-02-11 with a primary completion date of 2027-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

People tend to regulate intake by the weight of food rather than its energy content, making energy dense foods, especially those combining salty, fatty, and umami tastes, more likely to promote passive overconsumption. Lowering energy density can reduce daily energy intake, but often decreases palatability, whereas umami can enhance palatability, and sometimes decrease food intake. This suggests that adding umami to a regular energy dense diet could reduce food intake over time, and that adding umami to a reduced energy dense diet could sustain palatability and limit compensatory energy intake. Therefore, the aim of this study is to assess the effect of a 2-week dietary intervention of adding umami and/or lowering energy density on food intake. Secondary objectives are whether adding umami and/or lowering energy density affect dietary satisfaction, appetite, perceived umami intensity, food preferences, bodyweight and composition, and wellbeing ratings. This will assessed in a double-blind crossover, randomized controlled trial of three times two weeks, each separated by two weeks washout in 33 healthy Dutch adults between 18-65 years of age, with a BMI between 20-30. Umami taste will be added through MSG supplementation of the three main meals. Supplementation will depend on both intervention group, and individual participants' body weight. Energy density will be lowered by swapping regular products for low-fat, low-sugar or higher water products. The three intervention diets will vary in umami taste intensity, and/or energy density: 1) regular energy density without added umami (control), 2) regular energy density with added umami, 3) reduced energy density with added umami. Umami will be supplemented by supplementing food items with 55-60 mg MSG per kg bodyweight daily, divided over three eating occasions. Foods will be offered ad libitum, and participants will add a seasoning sachet containing MSG to their selected portion. The primary objective will be to compare average daily food intake (kcal) over two weeks between the three dietary interventions differing in umami taste intensity and energy density. Secondary outcomes are dietary satisfaction, appetite, perceived umami intensity, food preferences, bodyweight and composition, and wellbeing ratings.

Eligibility Criteria

Inclusion Criteria: * Healthy: as judged by the participant; * Age 16-65 years at the time of inclusion, assessed by date of birth; * Proper understanding of the Dutch language, as questionnaires will be in Dutch; * Able to visit Wageningen University, as required for dietary intervention and testing; * Body mass index 20-30 kg/m2; * Having normal taste ability, assessed using Mueller taste strip test, ≥12 out of 20 assessed correctly. Exclusion Criteria: * Suffering from endocrine- or gastro-intestinal diseases or other diseases that might influence study outcomes (such as diabetes, Crohn's disease, cardiovascular disease, hypertension, etc.); * Diagnosed with eating disorders (currently or in the past); * Diagnosed with taste or smell disorders in the past six months; * Pregnant or lactating during the study intervention; * Following a strict dietary regime; * Extreme physical activity (\>10 hours per week moderate/high intensity exercise); * Gain or loss of more than 5 kgs in the last six months prior to study entry; * Suffering from lack of appetite for any reason; * Use of medication that may influence the appetite (medication will be judged by the medical investigator); * Having a food allergy and/or intolerance for foods used in the dietary intervention (e.g. lactose intolerance, gluten intolerance, MSG sensitivity). This will be assessed with an open question; * Consumes more than 14 (women) or 21 (men) glasses of alcohol per week; * Consumes MSG-rich sauces (soy sauce, ketjap and/or curry paste) more than once per day, or consumes more than 3 savoury food items (paprika chips, instant noodles, sundried tomatoes and/or pre-packaged seasonings) per day. This will be assessed with a frequency of consumption table; * Irregular eating pattern. This will be measured with a frequency of meal/food consumption table, and is defined as: frequency of breakfast consumption less than once per week; * Unwilling to maintain regular exercise pattern during the study period. This will be assessed with a yes/no question; * Unwilling to quit use of soft or hard drugs during the intervention; * Student or personnel of the division of Human Nutrition and Health, Wageningen University; * Participating in any other intervention study/studies or planning to participate in another intervention study during the study period.

Contact & Investigator

Central Contact

Merel J. van der Kruijssen, Msc

✉ merel.vanderkruijssen@wur.nl

📞 +31 6 1289431

Frequently Asked Questions

Who can join the NCT07438028 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Sensory Testing. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07438028 currently recruiting?

Yes, NCT07438028 is actively recruiting participants. Contact the research team at merel.vanderkruijssen@wur.nl for enrollment information.

Where is the NCT07438028 trial being conducted?

This trial is being conducted at Wageningen, Netherlands.

Who is sponsoring the NCT07438028 clinical trial?

NCT07438028 is sponsored by Wageningen University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology